Providing a computing environment for a high energy physics workshop

Although computing facilities have been provided at conferences and workshops remote from the host institution for some years, the equipment provided has rarely been capable of providing for much more than simple editing and electronic mail. This report documents the effort involved in providing a local computing facility with world-wide networking capability for a physics workshop so that we and others can benefit from the knowledge gained through the experience

The Fermilab experience: Integration of UNIX systems in a HEP computing environment

There is an increased emphasis within organizations to migrate to a distributed computing environment. Among the factors responsible for this migration are: (1) a proliferation of high performance systems based on processors such as the Intel 80{times}86, Motorola 680{times}0, RISC architecture CPU's such as MIPS R{times}000, Sun SPARC, Motorola 88000 and Intel 860 series; (2) a significant reduction in hardware costs; (3) configuration based on existing local area network technology; and (4) the same (to a large extent) operating system on all platforms. A characteristic of distributed computing is that communication takes the form of request-reply pairs. This is also referred to as the client-server model. The client-server model is rapidly growing in popularity and in many scientific and engineering environments is replacing transaction-based and mainframe systems. Over the last few years, Fermilab has been in the process of migrating to a client-server model of computing

The Use of Anti-CD3 Treatment and Genetic Screening to Delay Further Beta Cell Destruction in Type 1 Diabetes

Individuals under 20 years old have the highest risk of developing type 1 diabetes because their beta cells are destroyed at a faster rate than any other age group. Previous studies have looked at delaying and slowing down the rate of beta cell destruction through the use of anti-CD3 antibody treatments. Specifically, Teplizumab and Otelixizumab drug therapies have been used to treat individuals within 12 weeks of diagnosis. Previous studies done with Teplizumab and Otelixizumab have focused on individuals between 12 and 40 years old; however, there is little research done the effects of these treatments on individuals under 12 years old. Since type 1 diabetes is primarily diagnosed in children the purpose of this proposal is to further the knowledge of the preservation of beta cells in children with the use of Teplizumab and Otelixizumab drugs over 2 years. This study will also focus on the delay of onset type 1 diabetes with the use of Teplizumab in high-risk individuals under 20 years of age. The high-risk individuals will be determined by using genetic screening on individuals with an affected immediate family member. Individuals will also be tested to see if they carry insulin autoantibodies (IAA), protein tyrosine phosphate-related IA-2 molecule (IA-2A), islet cell antibodies (ICA), and glutamic acid decarboxylase (GADA). Individuals that test positive for carrying the DR3/DR4 alleles in the genetic screening and that have two or more autoantibodies present in their immune systems will be selected to participate. The purpose of this proposal is to further understand the impact of anti-CD3 antibody treatment on young individuals diagnosed with type 1 diabetes and to further understand if treatment in young individuals with anti-CD3 antibodies can delay or prevent the onset of type 1 diabetes